Literature DB >> 4055056

Bone and joint infections caused by gram-positive bacteria: treatment with cefotaxime.

J LeFrock, J Mader, B Smith, B Carr.   

Abstract

Cefotaxime treatment was evaluated in 41 patients with serious bone and joint infections. Septic arthritis and bursitis (8), acute and chronic osteomyelitis (33) were treated with 3 to 12 g of cefotaxime per day for three to 52 days. The diagnosis of osteomyelitis or septic arthritis was made on the basis of clinical and roentgenographic evidence of infection. The diagnosis of a joint infection was confirmed by a positive culture of a joint aspirate sample. The diagnosis of a bone infection was confirmed by either a positive culture of a bone biopsy or of blood in combination with a positive bone scan or roentgenogram. Staphylococcus aureus was the most frequently isolated pathogen. Overall, 36 of 41 patients, who met all criteria for evaluation, had satisfactory responses to cefotaxime. The drug was well tolerated by all patients. However, six patients had a direct Coomb's test, two patients were noted to be neutropenic and two patients developed a macular rash. It is concluded that cefotaxime is a useful and safe antibiotic for the treatment of osteomyelitis and septic arthritis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4055056     DOI: 10.1007/BF01644219

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  10 in total

1.  Letter: Cephalothin-induced granulocytopenia.

Authors:  M A DiCato; L Ellman
Journal:  Ann Intern Med       Date:  1975-11       Impact factor: 25.391

2.  beta-lactamase stability of HR 756, a novel cephalosporin, compared to that of cefuroxime and cefoxitin.

Authors:  K P Fu; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1978-09       Impact factor: 5.191

3.  NEUTROPENIC REACTION TO CEPHALOTHIN THERAPY.

Authors:  A DAVIS; S J SELIGMAN; W L HEWITT; S M FINEGOLD
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1963

4.  Cefotoxime (HR 756) a new cephalosporin with exceptional broad-spectrum activity in vitro.

Authors:  J M Hamilton-Miller; W Brumfitt; A V Reynolds
Journal:  J Antimicrob Chemother       Date:  1978-09       Impact factor: 5.790

Review 5.  Antibiotic and pseudomembranous colitis.

Authors:  S P Borriello; H E Larson
Journal:  J Antimicrob Chemother       Date:  1981-06       Impact factor: 5.790

6.  HR 756, the syn isomer of a new methoxyimino cephalosporin with unusual antibacterial activity.

Authors:  Y A Chabbert; A J Lutz
Journal:  Antimicrob Agents Chemother       Date:  1978-11       Impact factor: 5.191

7.  Clinical experience with cefotaxime in the treatment of serious bone and joint infections.

Authors:  J L LeFrock; B B Carr
Journal:  Rev Infect Dis       Date:  1982 Sep-Oct

8.  Cephalosporin-associated pseudomembranous colitis.

Authors:  J F Tures; W F Townsend; H D Rose
Journal:  JAMA       Date:  1976-08-23       Impact factor: 56.272

9.  HR 756, a new cephalosporin active against gram-positive and gram-negative aerobic and anaerobic bacteria.

Authors:  H C Neu; N Aswapokee; P Aswapokee; K P Fu
Journal:  Antimicrob Agents Chemother       Date:  1979-02       Impact factor: 5.191

10.  The sensitivity of gentamicin-resistant gram-negative bacilli to cefotaxime, other cephalosporins and aminoglycosides.

Authors:  M Stephens; M Potten; A J Bint
Journal:  Infection       Date:  1979       Impact factor: 3.553

  10 in total
  3 in total

Review 1.  Rational prescribing of antibacterials in hospitalised children.

Authors:  J E Hoppe
Journal:  Pharmacoeconomics       Date:  1996-12       Impact factor: 4.981

Review 2.  Cefotaxime. An update of its pharmacology and therapeutic use.

Authors:  P A Todd; R N Brogden
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

3.  Drug Target Identification and Elucidation of Natural Inhibitors for Bordetella petrii: An In Silico Study.

Authors:  Surya Narayan Rath; Manisha Ray; Animesh Pattnaik; Sukanta Kumar Pradhan
Journal:  Genomics Inform       Date:  2016-12-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.